Entering text into the input field will update the search result below

BioDelivery Sciences announces notice of allowance of patent strengthening on BELBUCA to 2032

  • The U.S. Patent and Trademark Office issues a Notice of Allowance to BioDelivery Sciences International's (NASDAQ:BDSI) patent application, that once formally granted, will be Orange Book listed and will extend the exclusivity of BELBUCA (buprenorphine) buccal film from July 2027 to December 2032.
  • The patent covers the method of using BioErodible MucoAdhesive for the treatment of chronic pain.
  • Shares are up 9% premarket on light volume.

Recommended For You

Related Stocks

SymbolLast Price% Chg
BDSI--
BioDelivery Sciences International, Inc.